31 related articles for article (PubMed ID: 35390538)
1. Macro CD5L
Lu JC; Wu LL; Sun YN; Huang XY; Gao C; Guo XJ; Zeng HY; Qu XD; Chen Y; Wu D; Pei YZ; Meng XL; Zheng YM; Liang C; Zhang PF; Cai JB; Ding ZB; Yang GH; Ren N; Huang C; Wang XY; Gao Q; Sun QM; Shi YH; Qiu SJ; Ke AW; Shi GM; Zhou J; Sun YD; Fan J
Nat Commun; 2024 Jan; 15(1):621. PubMed ID: 38245530
[TBL] [Abstract][Full Text] [Related]
2. Diffuse Fasciitis of the Lower Extremities Possibly Induced by Gemcitabine in a Patient with Cholangiocarcinoma.
Yamamoto T
Actas Dermosifiliogr; 2024 Apr; 115(4):T412-T413. PubMed ID: 38325541
[No Abstract] [Full Text] [Related]
3. Diffuse Fasciitis of the Lower Extremities Possibly Induced by Gemcitabine in a Patient With Cholangiocarcinoma.
Yamamoto T
Actas Dermosifiliogr; 2024 Apr; 115(4):412-413. PubMed ID: 36933613
[No Abstract] [Full Text] [Related]
4. Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials.
Karasic TB; Eads JR; Goyal L
JCO Precis Oncol; 2023 Apr; 7():e2200573. PubMed ID: 37053534
[No Abstract] [Full Text] [Related]
5. Understanding Barriers to Enrollment in Adjuvant Clinical Trials: Insights into Patient Eligibility Criteria from the Adjuvant S-1 for Cholangiocarcinoma Trial (JCOG1202, ASCOT).
Sood D; Mayo SC
Ann Surg Oncol; 2023 Nov; 30(12):6967-6969. PubMed ID: 37684366
[No Abstract] [Full Text] [Related]
6. SIRT and chemotherapy in unresectable iCCA: Ready to take off.
Bargellini I; Rimassa L; Masi G
Hepatology; 2024 Jan; 79(1):9-11. PubMed ID: 37979204
[No Abstract] [Full Text] [Related]
7. [Long-surviving patient with hilar cholangiocarcinoma by gemcitabine monotherapy].
Iwata N; Yoshida T; Katsuta E; Aoyagi H; Takahata T; Hasegawa K; Kaneko J; Maejima S
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2116-8. PubMed ID: 23267995
[TBL] [Abstract][Full Text] [Related]
8. [A case of intrahepatic cholangiocarcinoma with invasion to right adrenal gland].
Iwagami Y; Marubashi S; Wada H; Kobayashi S; Eguchi H; Tanemura M; Umeshita K; Doki Y; Mori M; Nagano H
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2463-5. PubMed ID: 22202414
[TBL] [Abstract][Full Text] [Related]
9. Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience.
Ghiringhelli F; Lorgis V; Vincent J; Ladoire S; Guiu B
Chemotherapy; 2013; 59(5):354-60. PubMed ID: 24821200
[TBL] [Abstract][Full Text] [Related]
10. Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma.
Bralet MP; Bellin MF; Guettier C; Adam R; Paule B
Clin Oncol (R Coll Radiol); 2006 Jun; 18(5):426. PubMed ID: 16817335
[No Abstract] [Full Text] [Related]
11. Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy.
Vogl TJ; Schwarz W; Eichler K; Hochmuth K; Hammerstingl R; Jacob U; Scheller A; Zangos S; Heller M
J Cancer Res Clin Oncol; 2006 Nov; 132(11):745-55. PubMed ID: 16858591
[TBL] [Abstract][Full Text] [Related]
12. Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma.
Yang X; Pan J; Zhao H
JAMA Oncol; 2020 Jun; 6(6):935. PubMed ID: 32271359
[No Abstract] [Full Text] [Related]
13. Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma-Reply.
Cercek A; Jarnagin WR
JAMA Oncol; 2020 Jun; 6(6):935-936. PubMed ID: 32271367
[No Abstract] [Full Text] [Related]
14. Pathological complete response of liver metastases of cholangiocarcinoma using hepatic intra-arterial gemcitabine-oxaliplatin.
Bran DM; Fuks D; Lansier A; Gallois C; Karoui M; Taieb J; Lahlou W
Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):101920. PubMed ID: 35390538
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
